Red Spruce Capital LLC Sells 78 Shares of Eli Lilly and Company (NYSE:LLY)

Red Spruce Capital LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,287 shares of the company’s stock after selling 78 shares during the period. Red Spruce Capital LLC’s holdings in Eli Lilly and Company were worth $2,026,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Twelve Points Wealth Management LLC lifted its holdings in Eli Lilly and Company by 1.4% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 811 shares of the company’s stock worth $734,000 after buying an additional 11 shares during the period. Verum Partners LLC lifted its stake in Eli Lilly and Company by 1.5% in the second quarter. Verum Partners LLC now owns 731 shares of the company’s stock worth $662,000 after acquiring an additional 11 shares during the period. Beaird Harris Wealth Management LLC increased its position in shares of Eli Lilly and Company by 2.2% during the second quarter. Beaird Harris Wealth Management LLC now owns 512 shares of the company’s stock valued at $464,000 after buying an additional 11 shares during the period. Acorn Creek Capital LLC raised its stake in Eli Lilly and Company by 1.3% in the second quarter. Acorn Creek Capital LLC now owns 927 shares of the company’s stock worth $840,000 after buying an additional 12 shares in the last quarter. Finally, Thompson Davis & CO. Inc. lifted its holdings in Eli Lilly and Company by 0.7% in the second quarter. Thompson Davis & CO. Inc. now owns 1,687 shares of the company’s stock worth $1,527,000 after buying an additional 12 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $1.61 during trading hours on Friday, reaching $887.16. The company had a trading volume of 1,971,436 shares, compared to its average volume of 3,031,093. The firm has a market cap of $843.16 billion, a price-to-earnings ratio of 130.66, a PEG ratio of 2.78 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The firm’s 50 day moving average price is $900.13 and its 200-day moving average price is $847.87. Eli Lilly and Company has a 52 week low of $531.61 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. On average, analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on LLY. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Barclays increased their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Citigroup assumed coverage on Eli Lilly and Company in a research report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price target on the stock. Finally, Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.